Gardasil® HPV vaccine approved for the prevention of anal cancer
Sanofi Pasteur MSD announced today that the European Commission has granted marketing authorisation for the use of Gardasil® (human papillomavirus vaccine [types 6, 11, 16, 18] [recombinant, adsorbed]) for the prevention of anal precancerous lesions and anal cancers causally related to certain oncogenic human papillomavirus types in both males and females.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Oncology anal cancer gardasil hpv human papillomavirus Latest News Sanofi Pasteur MSD Source Type: news
More News: Anal Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer Vaccine | Drugs & Pharmacology | Gardasil | Genital Warts | Human Papillomavirus (HPV) | Marketing | Vaccines